Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease
|ClinicalTrials.gov Identifier: NCT01894438|
Recruitment Status : Completed
First Posted : July 10, 2013
Last Update Posted : August 3, 2017
|First Submitted Date ICMJE||July 3, 2013|
|First Posted Date ICMJE||July 10, 2013|
|Last Update Posted Date||August 3, 2017|
|Start Date ICMJE||April 2013|
|Primary Completion Date||May 2017 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Serum levels of alanine aminotransferase (ALT) [ Time Frame: Within 6 months ]
Clinically useful reduction in ALT, defined as the restoration of ALT within normal limits or reduction of ALT in >50% of its initial value.
|Original Primary Outcome Measures ICMJE
||Serum levels of alanine aminotransferase (ALT). [ Time Frame: Within 6 months ]
The primary endpoint will be a clinically useful reduction in ALT, defined as the restoration of ALT within normal limits or reduction of ALT in >50% of its initial value.
|Change History||Complete list of historical versions of study NCT01894438 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE
||Alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), liver stiffness, histological disease activity [ Time Frame: Within 6 months ]
Secondary endpoints will be:
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease|
|Official Title ICMJE||Effect of a Mediterranean Lifestyle Intervention on Biochemical and Clinical Characteristics of Patients With Non-alcoholic Fatty Liver Disease.|
Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of the metabolic syndrome. NAFLD is a pathologic condition which involves both hepatic steatosis and non alcoholic steatohepatitis (NASH), as the result of fat accumulation in the liver (liver fat >5-10% of liver weight), not due to excess alcohol consumption or other causes of steatosis.
At present, no medication or surgical procedure has been approved for treating NAFLD and lifestyle modifications remain the cornerstone therapy targeting both at weight reduction for overweight subjects and at prevention of overweight for the normal weight individuals. Given that a Mediterranean dietary pattern has a beneficial effect both on the prevention and the resolution of the metabolic syndrome, the main aim of the present study is to implement and evaluate the potential benefits of an intervention based on the Mediterranean lifestyle in a sample of patients with NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is a pathologic condition which involves both hepatic steatosis and non alcoholic steatohepatitis (NASH), as the result of fat accumulation in the liver (liver fat >5-10% of liver weight), not due to excess alcohol consumption or other causes of steatosis. Its prevalence ranges in the general population from 10-35%, while in obese individuals can reach the 75% and is particularly worrying because these people appear to have a higher mortality from both liver and non-liver-related disease, such as cardiovascular disease, and therefore a greater economic burden of health costs.
At present, no medication or surgical procedure has been approved for treating NAFLD and lifestyle modifications remain the cornerstone therapy targeting both at weight reduction for overweight subjects and at prevention of overweight for the normal weight individuals. Given that a Mediterranean dietary pattern has a beneficial effect both on the prevention and the resolution of the metabolic syndrome, the main aim of the present study is to implement and evaluate the potential benefits of an intervention based on the Mediterranean lifestyle in a sample of patients with NAFLD. A secondary aim will be to produce material, for both health professionals (namely dietitians and doctors) and patients to help them implementing such an intervention based on the Mediterranean lifestyle.
This study will be a prospective, randomized, blinded and controlled study. Participants with NAFLD and BMI>25Kg/m2 (range 25-40 Kg/m2) will be included. NAFLD's diagnosis will be based on increased serum levels of alanine aminotransferase (ALT), with or without increased gamma-glutamyl transpeptidase (GGT) serum levels, the presence of hepatic steatosis and absence of other causes of hepatic steatosis and hepatic failure.
At baseline, patients will be informed about the study and will give their written consent. Then subjects will be randomly assigned to one of 3 groups: (a) Control group, receiving written general advice for a healthy lifestyle; (b) Mediterranean diet Group or (c) Mediterranean lifestyle group. Participants in (b) and (c) groups will attend a more comprehensive program, comprising seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation. Participants will be also assessed 12 months after their entry in the study.
The dietary intervention and the monitoring will be carried out in the laboratory of Clinical Nutrition & Dietetics at Harokopio University, where experienced clinical dietitians will conduct all consultations. Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted, whereas in the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed. Intervention will also aim at achieving a 5-10% weight loss within the first 6 months.
Patients will be evaluated at baseline, at the end of the 6-mo intervention and 1 year after the study entry. At baseline, all patients will undergo a brief medical history assessment, complete physical examination and routine laboratory testing. History of alcohol consumption will be obtained from both patients and friends/relatives where possible. Evaluation of anthropometric measurements, dietary intake, physical activity and lifestyle habits, will be continuously assessed throughout the study. Dietary intake will be assessed through two 24-hour recalls and a food frequency questionnaire (FFQ). Data from recalls will be analyzed in terms of energy, macro- and micronutrient intake (using the Nutritionist Pro, version 2.2 software), as well as of food group intake and meal patterns. Conditions around eating will be also recorded and analyzed. Furthermore, a semi-quantitative FFQ, including the main food groups of the Mediterranean diet will be used for the overall assessment of eating habits. Physical activity will be assessed using the Harokopio Physical Activity Questionnaire (HPAQ). Sleep duration and quality will be evaluated through the Athens Insomnia Scale, consisting of items related to sleep induction, awakenings during the night, final awakening, total sleep duration, and sleep quality, well-being, functioning capacity, and sleepiness during the day. Current and past smoking habits will be also recorded.
At baseline and at 6 and 12 months, blood samples will be collected after an overnight food deprivation for the assessment of biochemical markers, and stored at -80oC. Lipid profile, markers of glucose metabolism and liver function, and adipokines, inflammatory markers and markers of oxidative stress will be determined using automated analyzers and/or commercial ELISA kits.
All patients will pass through liver stiffness measurements with liver elastography at baseline, as well as at the end of the intervention and after one year of the study entry. Patients without a recent liver biopsy (within the previous 12 months) will also undergo liver biopsy at baseline. Liver biopsies will be repeated one year after and will be evaluated by the same hepato-pathologist, who will have access to patient's clinical data.
|Study Type ICMJE||Interventional|
|Study Phase||Not Provided|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Completion Date||May 2017|
|Primary Completion Date||May 2017 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
The inclusion criteria will be:
The exclusion criteria will be:
|Ages||18 Years to 65 Years (Adult)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Greece|
|Removed Location Countries|
|NCT Number ICMJE||NCT01894438|
|Other Study ID Numbers ICMJE||LD-0098|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||
|Responsible Party||Meropi Kontogianni, Harokopio University|
|Study Sponsor ICMJE||Harokopio University|
|Collaborators ICMJE||University of Athens|
|PRS Account||Harokopio University|
|Verification Date||August 2017|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP